LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER
Clinical trials for LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple therapy aims to boost survival in Hard-to-Treat stomach cancers
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced stomach or gastroesophageal junction (GEJ) cancer live longer. The study enrolls 500 adults whose tumors have specific m…
Matched conditions: LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New study tracks safety of VYLOY in everyday cancer care
Disease control Recruiting nowThis study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's …
Matched conditions: LOCALLY ADVANCED UNRESECTABLE GASTRIC ADENOCARCINOMA OR CANCER
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC